Botulinum Toxin Therapy in Hidradenitis Suppurativa
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorUniversity of Massachusetts, Worcester
About this trial
This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.
Eligibility criteria
Qualifiers
Adults between ages 18 and 75 years with established diagnosis of hidradenitis suppurativa (HS)
HS skin lesions of duration at least 1 year, HS skin lesions in at least two different body areas
Age < 18 years or > 75 years
pregnant or breastfeeding
Disqualifiers
None
Trial design
Treatments tested in this trial
- Botulinum toxin
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Massachusetts, Worcester
Lead sponsor
Hidradenitis Suppurativa Foundation
Collaborator
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Collaborator
AbbVie
Collaborator
Source ClinicalTrials.gov